本文選題：艾塞那肽 + 2型糖尿病　； 參考：《廣西醫(yī)科大學(xué)》2017年碩士論文

【摘要】：目的:研究艾塞那肽對(duì)2型糖尿病患者血管內(nèi)皮功能及心血管疾病相關(guān)危險(xiǎn)因素的影響。方法:將初發(fā)的2型糖尿病患者隨機(jī)分為兩組,一組為對(duì)照組,給予指導(dǎo)飲食,調(diào)整飲食結(jié)構(gòu),合理運(yùn)動(dòng);一組艾塞那肽治療組,給予艾塞那肽皮下注射治療,前4周給予艾塞那肽5ug/次,早晚餐前各一次,后8周10ug/次,早晚餐前各一次,共12周,觀察治療前后血管內(nèi)皮功能相關(guān)指標(biāo),如可溶性細(xì)胞間粘附分子(s ICAM-1)、可溶性血管細(xì)胞間粘附分子(s VCAM-1)及單核細(xì)胞趨化因子(MCP-1),肱動(dòng)脈血流介導(dǎo)的血管舒張功能(FMD);同時(shí)監(jiān)測(cè)治療前后心血管疾病相關(guān)的代謝性指標(biāo),如空腹血糖、空腹C肽、糖化血紅蛋白(Hb Ac1),總膽固醇、甘油三酯、低密度脂蛋白膽固醇、高密度脂蛋白膽固醇,體重、體質(zhì)指數(shù)、腹圍。結(jié)果:對(duì)照組治療前后s ICAM-1、s VCAM-1、MCP-1、FMD水平差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05);艾塞那肽組治療12周后較治療前s ICAM-1、s VCAM-1、MCP-1水平下降,FMD升高,且差異有統(tǒng)計(jì)學(xué)意義(P0.05);治療12周后艾塞那肽組較對(duì)照組s ICAM-1、s VCAM-1、MCP-1水平下降(P0.05),FMD升高(P0.05)。對(duì)照組治療治療前后空腹血糖、糖化血紅蛋白(Hb Ac1)、總膽固醇、甘油三酯、低密度脂蛋白膽固醇、體重、體質(zhì)指數(shù)、腹圍、空腹C肽水平差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05);艾塞那肽組治療12周后較治療前比較空腹血糖、糖化血紅蛋白(Hb Ac1)、總膽固醇、甘油三酯、低密度脂蛋白膽固醇、體重、體質(zhì)指數(shù)、腹圍水平下降,空腹C肽水平上升,且差異有統(tǒng)計(jì)學(xué)意義(P0.05);兩組高密度脂蛋白膽固醇升高,但差異均無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論:艾塞那肽能改善心血管疾病相關(guān)的代謝異常,對(duì)血管內(nèi)皮功能有一定保護(hù)作用,可能一定程度的預(yù)防和減慢心血管事件的發(fā)生及發(fā)展。
[Abstract]:Aim: to study the effects of Isenapeptide on vascular endothelial function and cardiovascular risk factors in patients with type 2 diabetes mellitus. Methods: the patients with type 2 diabetes mellitus were randomly divided into two groups: the control group, the control group and the control group. In the first 4 weeks, Isenapeptide 5ug/ was given once before morning and evening, once before meal, 8 weeks after meal, and once before morning and evening for 12 weeks. The relative indexes of vascular endothelial function were observed before and after treatment. Such as soluble intercellular adhesion molecule (sICAM-1), soluble vascular intercellular adhesion molecule (sVCAM-1), monocyte chemokine (MCP-1), brachial artery flow-mediated vasodilation (FMD), metabolic indexes related to cardiovascular disease before and after treatment. Such as fasting blood glucose, fasting C-peptide, glycosylated hemoglobin (HB Ac1), total cholesterol, triglyceride, low density lipoprotein cholesterol, high density lipoprotein cholesterol, body mass, body mass index, abdominal circumference. Results: there was no significant difference in the level of FMD between control group and control group before and after treatment (P0.05), and the level of MCP-1 decreased and FMD increased after 12 weeks of treatment in Eisenapeptide group. And the difference was statistically significant (P0.05); after 12 weeks of treatment, the level of MCP-1 in the Eisenapeptide group was significantly lower than that in the control group (P0.05). In the control group, fasting blood glucose, HB Ac1, total cholesterol, triglyceride, low density lipoprotein cholesterol, body weight, body mass index, abdominal circumference were measured before and after treatment. There was no significant difference in fasting C-peptide level (P0.05), fasting blood glucose, glycosylated hemoglobin (HB Ac1), total cholesterol, triglyceride, low density lipoprotein cholesterol, body weight, body mass index (BMI) were compared after 12 weeks of treatment in Eisenapeptide group. Abdominal circumference level decreased, fasting C-peptide level increased, and the difference was statistically significant (P0.05); two groups of high density lipoprotein cholesterol increased, but the difference was not statistically significant (P0.05). Conclusion: Isenapeptide can improve the metabolic abnormalities associated with cardiovascular disease and protect vascular endothelial function. It may prevent and slow down the occurrence and development of cardiovascular events to some extent.
【學(xué)位授予單位】：廣西醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R587.1

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 黃新梅;劉軍;;腸促胰島素相關(guān)藥物的臨床作用研究進(jìn)展[J];上海醫(yī)藥;2013年07期

2 嚴(yán)國(guó)文;李謙;何書(shū)英;朱杰;吳梧桐;;抗糖尿病肽類藥物研究進(jìn)展[J];藥物生物技術(shù);2012年03期

3 李珊;鄭麗麗;李沖;;胰高血糖素樣肽1受體激動(dòng)劑對(duì)高糖誘導(dǎo)的血管內(nèi)皮細(xì)胞NF-κB、ICAM-1和VCAM-1表達(dá)的影響[J];中國(guó)動(dòng)脈硬化雜志;2012年04期

4 胡玲;沈浩;;艾塞那肽治療肥胖2型糖尿病23例臨床分析[J];中國(guó)實(shí)用內(nèi)科雜志;2012年04期

5 林楊;葉山東;;單核細(xì)胞趨化蛋白-1與糖尿病動(dòng)脈粥樣硬化的關(guān)系[J];國(guó)際內(nèi)科學(xué)雜志;2007年07期

6 于杰;楊梅;楊萍;齊玲;姜鐵超;;高分辨力超聲檢測(cè)冠心病血管內(nèi)皮功能的臨床應(yīng)用[J];吉林大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2006年03期

7 周興建;蔣綠芝;;MCP-1與胰島素抵抗和2型糖尿病的關(guān)系[J];國(guó)際內(nèi)分泌代謝雜志;2006年02期

8 劉惠俠;曾璐琳;;新型降糖藥exenatide的研究進(jìn)展[J];世界臨床藥物;2005年11期

9 朱彥琪,孫寶貴;可溶性細(xì)胞間粘附分子和可溶性血管細(xì)胞粘附分子與動(dòng)脈粥樣硬化[J];中國(guó)動(dòng)脈硬化雜志;2004年05期

10 Jianglin Fan,Teruo Watanabe,王燕翻;炎癥反應(yīng)在動(dòng)脈粥樣硬化發(fā)病學(xué)中的作用[J];中國(guó)動(dòng)脈硬化雜志;2003年S1期

，

本文編號(hào)：2082278